Jardiance vs Farxiga in Special Populations: A Head-to-Head Clinical Comparison

What Do Jardiance and Farxiga Actually Do Differently?

Both drugs block the SGLT2 transporter in the proximal renal tubule, forcing urinary glucose excretion of roughly 60-80 grams per day and producing a modest osmotic diuresis. That shared mechanism produces similar A1C reductions, weight loss of 2-3 kg, and systolic blood pressure drops of 3-5 mmHg. The differences that matter clinically sit in their cardiovascular and renal outcomes trial data, their approved indications, and how each drug behaves at lower kidney function thresholds.

Mechanism and Pharmacokinetics

Empagliflozin reaches peak plasma concentration in about 1.5 hours and has a half-life of roughly 12.4 hours, supporting once-daily dosing [1]. Dapagliflozin peaks at approximately 2 hours with a half-life near 12.9 hours [2]. Both are primarily hepatically metabolized via UGT1A3 and UGT2B7, so renal impairment has minimal effect on drug exposure, even though the glucose-lowering efficacy diminishes as eGFR falls.

Glucose Lowering at Different eGFR Thresholds

Neither drug should be started for glycemic control alone when eGFR falls below 45 mL/min/1.73m2, though both retain cardiovascular and renal protective benefits at lower eGFR values. Dapagliflozin's package insert now permits use down to eGFR 25 for heart failure and CKD indications [3]. Empagliflozin's 2023 label update extended its CKD indication down to eGFR 20 [4]. Patients near these thresholds require individualized risk-benefit assessment.

Cardiovascular Outcomes: Where the Trial Data Diverge

The two drugs have distinct trial histories that shape prescribing in high-risk cardiovascular populations. Empagliflozin's EMPA-REG OUTCOME trial was published first and reported the more dramatic mortality reduction in patients with established atherosclerotic cardiovascular disease (ASCVD).

EMPA-REG OUTCOME (Empagliflozin)

EMPA-REG OUTCOME enrolled 7,020 adults with type 2 diabetes and established ASCVD [5]. After a median follow-up of 3.1 years, empagliflozin reduced the rate of CV death by 38% relative to placebo (3.7% vs 5.9%; HR 0.62, 95% CI 0.49-0.77; P<0.001 for superiority). Hospitalization for heart failure fell by 35%. The trial's investigators concluded: "Empagliflozin added to standard care resulted in significantly lower rates of the primary composite cardiovascular outcome, death from cardiovascular causes, and hospitalization for heart failure" [5].

Total mortality also declined, with a 32% relative reduction (HR 0.68, 95% CI 0.57-0.82). This all-cause mortality benefit has not been replicated at the same magnitude in other SGLT2 inhibitor trials, making empagliflozin the preferred choice in T2D patients with documented ASCVD who can tolerate 10-25 mg daily.

DECLARE-TIMI 58 (Dapagliflozin) in T2D

DECLARE-TIMI 58 enrolled 17,160 adults with T2D, of whom only 40.6% had established ASCVD while 59.4% had only CV risk factors [6]. The trial found no statistically significant reduction in major adverse cardiovascular events (MACE) in the overall population. However, dapagliflozin did reduce the combined rate of CV death or hospitalization for heart failure (HR 0.83, 95% CI 0.73-0.95; P = 0.005). That difference matters: dapagliflozin's cardiovascular benefit in T2D is largely driven by heart failure prevention rather than atherosclerotic event reduction.

For a patient with T2D and high CV risk but no prior MI or stroke, either agent is reasonable. For a patient with prior MI, the EMPA-REG data favor empagliflozin.

Heart Failure: Both Drugs Now Have Full Indications

HFrEF: EMPEROR-Reduced vs DAPA-HF

DAPA-HF (N = 4,744) established dapagliflozin 10 mg as an evidence-based therapy for heart failure with reduced ejection fraction (HFrEF, EF <40%), regardless of diabetes status [7]. The primary endpoint, a composite of worsening heart failure or CV death, was reduced by 26% (HR 0.74, 95% CI 0.65-0.85; P<0.001). The American College of Cardiology's 2022 heart failure guideline gave SGLT2 inhibitors a Class I, Level A recommendation for HFrEF based substantially on this trial.

EMPEROR-Reduced (N = 3,730) tested empagliflozin 10 mg in HFrEF (EF <40%) and showed a 25% reduction in the same composite endpoint (HR 0.75, 95% CI 0.65-0.86; P<0.001) [8]. The two trials are nearly identical in their relative risk reductions, which led the guidelines to treat the two drugs as interchangeable in HFrEF.

HFpEF: EMPEROR-Preserved vs DELIVER

This sub-population is where dapagliflozin established its label advantage first. DELIVER (N = 6,263) randomized patients with heart failure and EF above 40% to dapagliflozin 10 mg or placebo and showed a 18% relative reduction in worsening heart failure or CV death (HR 0.82, 95% CI 0.73-0.92; P<0.001) [9]. EMPEROR-Preserved (N = 5,988) showed a nearly identical result for empagliflozin: HR 0.79, 95% CI 0.69-0.90; P<0.001 [10]. The FDA granted both drugs HFpEF labeling based on these data.

For HFpEF, the two drugs show equivalent benefit and either is guideline-appropriate.

Chronic Kidney Disease: A Tighter Race With Recent Shifts

DAPA-CKD (Dapagliflozin)

DAPA-CKD (N = 4,304) enrolled patients with CKD (eGFR 25-75 mL/min/1.73m2 and urine albumin-to-creatinine ratio 200-5,000 mg/g), roughly two-thirds of whom had type 2 diabetes [11]. Dapagliflozin 10 mg reduced the composite of sustained eGFR decline of 50% or more, ESRD, CV death, or renal death by 39% compared to placebo (HR 0.61, 95% CI 0.51-0.72; P<0.001). The trial was stopped early due to efficacy. Non-diabetic CKD patients showed the same magnitude of benefit, confirming a kidney-protective effect independent of glycemic action.

EMPA-KIDNEY (Empagliflozin)

EMPA-KIDNEY (N = 6,609) enrolled a broader CKD population including patients with eGFR as low as 20 mL/min/1.73m2 [12]. Empagliflozin 10 mg reduced the composite of kidney disease progression or CV death by 28% (HR 0.72, 95% CI 0.64-0.82; P<0.001). Roughly 45% of enrolled patients had no diabetes, and benefit was consistent across diabetic and non-diabetic subgroups. The trial extended empagliflozin's relevant CKD treatment range to a lower eGFR floor than DAPA-CKD covered.

Which Drug for CKD?

The FDA approved dapagliflozin for CKD in April 2021 [3] and empagliflozin for CKD in March 2023 [4]. For patients with eGFR 25-45 and significant albuminuria, both are options. For patients with eGFR 20-25, empagliflozin's trial enrollment criteria make it the better-studied choice. Nephrologists at major academic centers have increasingly adopted both agents; the choice often defaults to formulary access and prior authorization pathways.

Elderly Patients: Special Considerations Over Age 65

Volume Depletion and Fall Risk

SGLT2 inhibitors cause a modest osmotic diuresis that can produce volume depletion, particularly in elderly patients on loop diuretics or ACE inhibitors. The FDA label for both drugs carries a warning about hypotension and urinary frequency in older adults. A 2020 pharmacovigilance analysis using FDA Adverse Event Reporting System (FAERS) data found that both empagliflozin and dapagliflozin were associated with urinary tract complaints and dehydration events at similar rates in patients over 65 [13].

Bone Fracture Signal

Canagliflozin (a related SGLT2 inhibitor) carries a boxed warning for fracture risk, but neither empagliflozin nor dapagliflozin has a similar label warning. DECLARE-TIMI 58 found no significant increase in fracture rates with dapagliflozin [6]. EMPA-REG OUTCOME showed no fracture signal for empagliflozin [5]. Prescribers should still assess fall risk independently in older patients before initiating either agent.

Dosing Adjustments in the Elderly

No dose adjustment is required based on age alone for either drug. Renal function, not chronological age, drives dosing decisions. Patients over 75 with eGFR below 45 should not expect meaningful glycemic benefit from either drug, but cardiovascular and renal protection remain relevant indications.

Type 2 Diabetes With Obesity: Weight and Metabolic Effects

Both drugs produce clinically meaningful weight loss through caloric loss in urine and modest reductions in fat mass. Pooled analysis across phase 3 trials places the mean weight reduction at approximately 2-3 kg for empagliflozin 10-25 mg [1] and 2-3 kg for dapagliflozin 10 mg [2]. Neither reduction rivals GLP-1 receptor agonists, which produce 5-15 kg of mean weight loss in dedicated obesity trials.

For patients with T2D and obesity who need both glucose lowering and meaningful weight reduction, combination therapy with a GLP-1 receptor agonist plus an SGLT2 inhibitor is frequently considered. The ADA's 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on therapy in T2D patients with heart failure or CKD, irrespective of baseline A1C [14].

Switching from Jardiance to Farxiga (or Vice Versa)

When a Switch Is Clinically Appropriate

Patients may need to switch drugs due to insurance formulary changes, tolerability issues, or a change in primary indication. A patient originally started on empagliflozin for T2D who subsequently develops HFpEF without prior MI may have no pharmacologic reason to switch; empagliflozin now carries an HFpEF indication. Conversely, a patient on dapagliflozin with eGFR declining toward 20 should confirm their current drug's CKD label supports continued use.

How to Switch Safely

The transition is typically straightforward. Stop empagliflozin and start dapagliflozin (or the reverse) the following morning at an equivalent or appropriate dose. No tapering is required for either drug. Prior authorization for the new agent should be confirmed before the first prescription is written.

Common reasons for switching include:

• Formulary tier change making one agent significantly cheaper
• Recurrent genital mycotic infections prompting a trial of the alternate agent (though class-wide risk is similar)
• Change in primary clinical indication that better matches one drug's trial data
• Prescriber or institutional preference based on outcomes data

The table below summarizes the key decision framework for selecting between the two agents across special populations.

| Population | Preferred Agent | Key Trial | Primary Reason | |---|---|---|---| | T2D + established ASCVD | Empagliflozin | EMPA-REG OUTCOME | 38% CV death reduction | | T2D + HF risk, no prior MI | Either | DECLARE / EMPA-REG | Comparable HF prevention | | HFrEF (any diabetes status) | Either | DAPA-HF / EMPEROR-Reduced | Near-identical HR ~0.75 | | HFpEF (any diabetes status) | Either | DELIVER / EMPEROR-Preserved | Near-identical HR ~0.80 | | CKD eGFR 25-45 | Either | DAPA-CKD / EMPA-KIDNEY | Both reduce progression | | CKD eGFR 20-25 | Empagliflozin | EMPA-KIDNEY | Lower eGFR enrollment | | T2D + obesity, no CV disease | Either | Multiple phase 3 trials | Equivalent weight effect | | Elderly, eGFR <45 | Either (CV/renal) | Post-hoc subgroup data | Glycemic benefit limited |

Safety Profile Comparison

Genital Mycotic Infections

The most common adverse effect for both drugs is genital mycotic infection, occurring in 3-8% of women and 1-3% of men across key trials [5,6]. Rates do not differ meaningfully between the two agents. Patients with recurrent infections may benefit from antifungal prophylaxis or improved genital hygiene rather than a class switch.

Diabetic Ketoacidosis

Both agents carry an FDA warning for euglycemic diabetic ketoacidosis (DKA), which occurs at low but non-trivial rates. DKA risk is highest in type 1 diabetes (neither drug is approved for T1D as monotherapy), in patients under significant physiologic stress, and in those who reduce insulin doses inappropriately. The FDA advises stopping both empagliflozin and dapagliflozin at least 3 days before planned surgery [3,4].

Fournier's Gangrene

A rare but serious necrotizing fasciitis of the genitalia has been reported with the entire SGLT2 inhibitor class. As of 2018, the FDA had identified 12 cases across all SGLT2 inhibitors. Both drugs carry the same class-wide warning [15].

Urinary Tract Infections

Upper UTI and urosepsis warnings appear on both labels. Lower UTI rates in trials were modestly elevated versus placebo but not dramatically so. Dapagliflozin showed a 5.7% UTI rate versus 4.3% for placebo in DECLARE-TIMI 58 [6].

Cost, Access, and Formulary Realities

Both Jardiance and Farxiga carry list prices exceeding $500 per month in the United States without insurance. Generic empagliflozin became available in 2024 following patent expiration challenges, and generic dapagliflozin may follow. Patient assistance programs from Boehringer Ingelheim and AstraZeneca can reduce out-of-pocket costs to near zero for eligible patients.

For Medicare Part D patients, formulary placement varies by plan year and region. The 2025 Medicare Drug Price Negotiation program has targeted several high-cost diabetes medications, and SGLT2 inhibitors remain under active pricing discussion. Checking real-time formulary status before prescribing is standard practice in most endocrinology and cardiology offices.

What Endocrinologists and Cardiologists Say

The ACC/AHA 2022 heart failure guidelines state: "In patients with symptomatic chronic HFrEF, we recommend SGLT2 inhibitors to reduce HF hospitalizations and CV mortality" with a Class I recommendation applied equally to empagliflozin and dapagliflozin [16].

The ADA's 2024 Standards of Care in Diabetes specify: "For patients with type 2 diabetes and established CVD or indicators of high CVD risk, an established kidney disease, or heart failure, a sodium-glucose cotransporter 2 inhibitor with demonstrated cardiovascular benefit is recommended" [14].

Neither major guideline specifies one SGLT2 inhibitor over the other for most indications, reflecting the genuine clinical equivalence across most outcomes.

Pregnancy, Lactation, and Reproductive-Age Patients

Both empagliflozin and dapagliflozin are contraindicated in the second and third trimesters of pregnancy due to fetal renal toxicity risk. Neither drug has adequate human lactation data; both manufacturers advise against use during breastfeeding [3,4]. For women of reproductive age with T2D, a contraception counseling conversation should precede initiation of either agent.